Trials / Completed
CompletedNCT04512053
A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of TAS-303 in Female Patients With Stress Urinary Incontinence
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 231 (actual)
- Sponsor
- Taiho Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.
Detailed description
The main purpose of this study is to assess the efficacy of TAS-303 in female patients with stress urinary incontinence (SUI) compared with placebo as measured by the percent change in the average SUI episode frequency per 24 hours from baseline at week 12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-303 18 mg/day | Oral administration for 12 weeks, once daily |
| DRUG | Placebo | Oral administration for 12 weeks, once daily |
Timeline
- Start date
- 2020-09-04
- Primary completion
- 2021-12-22
- Completion
- 2021-12-22
- First posted
- 2020-08-13
- Last updated
- 2022-02-10
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04512053. Inclusion in this directory is not an endorsement.